Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6205

1.

Tuberous sclerosis complex.

Peron A, Northrup H.

Am J Med Genet C Semin Med Genet. 2018 Oct 16. doi: 10.1002/ajmg.c.31657. [Epub ahead of print] No abstract available.

PMID:
30325570
2.

Tuberous sclerosis complex in a third level hospital: Need for integral management.

Bautista Alonso RE, Artajona Rodrigo E, Povar Echeverría M.

Med Clin (Barc). 2018 Oct 12. pii: S0025-7753(18)30513-X. doi: 10.1016/j.medcli.2018.08.004. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
30322651
3.

Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment.

McCann HD, Johnson CE, Errington RJ, Davies DM, Dunlop EA, Tee AR.

Cancers (Basel). 2018 Oct 10;10(10). pii: E375. doi: 10.3390/cancers10100375.

4.

Unilateral shortening of third metacarpal bone in a patient with tuberous sclerosis.

Azami A, Habibzadeh A.

Eur J Rheumatol. 2018 Oct 8:1-2. doi: 10.5152/eurjrheum.2018.18062. [Epub ahead of print] No abstract available.

PMID:
30308143
5.

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.

Franz DN, Krueger DA.

Am J Med Genet C Semin Med Genet. 2018 Oct 11. doi: 10.1002/ajmg.c.31655. [Epub ahead of print]

PMID:
30307123
6.

Renal manifestation of tuberous sclerosis complex.

Bissler JJ, Christopher Kingswood J.

Am J Med Genet C Semin Med Genet. 2018 Oct 11. doi: 10.1002/ajmg.c.31654. [Epub ahead of print]

PMID:
30307110
7.

The use of rapamycin in patients with tuberous sclerosis complex: Long-term results.

Canpolat M, Gumus H, Kumandas S, Coskun A, Per H.

Epilepsy Behav. 2018 Oct 7. pii: S1525-5050(18)30539-0. doi: 10.1016/j.yebeh.2018.09.020. [Epub ahead of print]

PMID:
30305233
8.

Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study.

Toldo I, Brasson V, Miscioscia M, Pelizza MF, Manara R, Sartori S, Mantegazza G, Vecchi M, Nosadini M, Gatta M.

Dev Med Child Neurol. 2018 Oct 9. doi: 10.1111/dmcn.14055. [Epub ahead of print]

PMID:
30298907
9.

High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex.

Hussain SA, Schmid E, Peters JM, Goyal M, Bebin EM, Northrup H, Sahin M, Krueger DA, Wu JY; Tuberous Sclerosis Complex Autism Center of Excellence Network.

Epilepsy Res. 2018 Oct 2;148:1-7. doi: 10.1016/j.eplepsyres.2018.09.016. [Epub ahead of print]

PMID:
30296632
10.

Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.

Rentz AM, Skalicky AM, Liu Z, Dunn DW, Frost MD, Nakagawa JA, Prestifilippo J, Said Q, Wheless JW.

J Patient Rep Outcomes. 2018 Jul 13;2:30. doi: 10.1186/s41687-018-0055-4. eCollection 2018 Dec.

11.

Diagnosis of tuberous sclerosis complex in the fetus.

Dragoumi P, O'Callaghan F, Zafeiriou DI.

Eur J Paediatr Neurol. 2018 Sep 12. pii: S1090-3798(18)30376-3. doi: 10.1016/j.ejpn.2018.08.005. [Epub ahead of print] Review.

PMID:
30279084
12.

MRI-guided laser interstitial thermal therapy in an infant with tuberous sclerosis: technical case report.

Hooten KG, Werner K, Mikati MA, Muh CR.

J Neurosurg Pediatr. 2018 Sep 28:1-6. doi: 10.3171/2018.6.PEDS1828. [Epub ahead of print]

PMID:
30265228
13.

Minimal mosaicism, maximal phenotype: Discordance between clinical and molecular findings in two patients with tuberous sclerosis.

Byers HM, Jensen DM, Glass IA, Bennett JT.

Am J Med Genet C Semin Med Genet. 2018 Sep 27. doi: 10.1002/ajmg.c.31656. [Epub ahead of print]

PMID:
30260069
14.

Giant Shagreen Patch in Tuberous Sclerosis Complex.

Kuntoji V, Bhagwat PV, Kudligi C.

Indian Dermatol Online J. 2018 Sep-Oct;9(5):353-355. doi: 10.4103/idoj.IDOJ_272_17. No abstract available.

15.

Current concepts on epilepsy management in tuberous sclerosis complex.

Canevini MP, Kotulska-Jozwiak K, Curatolo P, La Briola F, Peron A, Słowińska M, Strzelecka J, Vignoli A, Jóźwiak S.

Am J Med Genet C Semin Med Genet. 2018 Sep 26. doi: 10.1002/ajmg.c.31652. [Epub ahead of print]

PMID:
30255982
16.

Healthcare transition from childhood to adulthood in Tuberous Sclerosis Complex.

Peron A, Canevini MP, Ghelma F, Di Marco F, Vignoli A.

Am J Med Genet C Semin Med Genet. 2018 Sep 25. doi: 10.1002/ajmg.c.31653. [Epub ahead of print]

PMID:
30253036
17.

The UK guidelines for management and surveillance of Tuberous Sclerosis Complex.

Amin S, Kingswood JC, Bolton PF, Elmslie F, Gale DP, Harland C, Johnson SR, Parker A, Sampson JR, Smeaton M, Wright I, O'Callaghan FJ.

QJM. 2018 Sep 21. doi: 10.1093/qjmed/hcy215. [Epub ahead of print]

PMID:
30247655
18.

Tuberous sclerosis complex-mediated mTORC1 overactivation promotes age-related hearing loss.

Fu X, Sun X, Zhang L, Jin Y, Chai R, Yang L, Zhang A, Liu X, Bai X, Li J, Wang H, Gao J.

J Clin Invest. 2018 Sep 24. pii: 98058. doi: 10.1172/JCI98058. [Epub ahead of print]

19.

The cutaneous manifestations of tuberous sclerosis complex.

Nguyen QD, DarConte MD, Hebert AA.

Am J Med Genet C Semin Med Genet. 2018 Sep 23. doi: 10.1002/ajmg.c.31649. [Epub ahead of print]

PMID:
30246432
20.

Tuberous Sclerosis Complex Associated with Hemihypertrophy and Combined Vascular Malformations.

Flores-Terry MÁ, Alegre-Sánchez A, Boixeda P, López-Gutiérrez JC.

Actas Dermosifiliogr. 2018 Sep 20. pii: S0001-7310(18)30204-7. doi: 10.1016/j.ad.2017.12.010. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
30244874

Supplemental Content

Loading ...
Support Center